<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38126937</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>05</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-1654</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Reviews in medical virology</Title><ISOAbbreviation>Rev Med Virol</ISOAbbreviation></Journal><ArticleTitle>Targeting epidermal growth factor receptor signalling pathway: A promising therapeutic option for COVID-19.</ArticleTitle><Pagination><StartPage>e2500</StartPage><MedlinePgn>e2500</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/rmv.2500</ELocationID><Abstract><AbstractText>The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuously producing new variants, necessitating effective therapeutics. Patients are not only confronted by the immediate symptoms of infection but also by the long-term health issues linked to long COVID-19. Activation of epidermal growth factor receptor (EGFR) signalling during SARS-CoV-2 infection promotes virus propagation, mucus hyperproduction, and pulmonary fibrosis, and suppresses the host's antiviral response. Over the long term, EGFR activation in COVID-19, particularly in COVID-19-induced pulmonary fibrosis, may be linked to the development of lung cancer. In this review, we have summarised the significance of EGFR signalling in the context of SARS-CoV-2 infection. We also discussed the targeting of EGFR signalling as a promising strategy for COVID-19 treatment and highlighted erlotinib as a superior option among EGFR inhibitors. Erlotinib effectively blocks EGFR and AAK1, thereby preventing SARS-CoV-2 replication, reducing mucus hyperproduction, TNF-&#x3b1; expression, and enhancing the host's antiviral response. Nevertheless, to evaluate the antiviral efficacy of erlotinib, relevant clinical trials involving an appropriate patient population should be designed.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. Reviews in Medical Virology published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Razzaq</LastName><ForeName>Aroona</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, School of Life Sciences, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Disoma</LastName><ForeName>Cyrollah</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, School of Life Sciences, Central South University, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biology, College of Natural Sciences and Mathematics, Mindanao State University, Marawi City, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yuzheng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, School of Life Sciences, Central South University, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tao</LastName><ForeName>Siyi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, School of Life Sciences, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Zongpeng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, School of Life Sciences, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Sixu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, School of Life Sciences, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Rong</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, School of Life Sciences, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yongxing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, School of Life Sciences, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Yujie</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, School of Life Sciences, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, School of Life Sciences, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Sijie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, School of Life Sciences, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Zijun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, School of Life Sciences, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Liangtao</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, School of Life Sciences, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Xu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Xiangya School of Pharmaceutical Science, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Shanni</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, School of Life Sciences, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Zanxian</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0002-5810-1678</Identifier><AffiliationInfo><Affiliation>Department of Cell Biology, School of Life Sciences, Central South University, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hunan Key Laboratory of Animal Models for Human Diseases, School of Life Sciences, Central South University, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Central South University, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Medical Genetics, School of Life Sciences, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>12</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Rev Med Virol</MedlineTA><NlmUniqueID>9112448</NlmUniqueID><ISSNLinking>1052-9276</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>DA87705X9K</RegistryNumber><NameOfSubstance UI="D000069347">Erlotinib Hydrochloride</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066246" MajorTopicYN="Y">ErbB Receptors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069347" MajorTopicYN="N">Erlotinib Hydrochloride</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011658" MajorTopicYN="N">Pulmonary Fibrosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">EGFR inhibitor</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">epidermal growth factor receptor (EGFR) activation</Keyword><Keyword MajorTopicYN="N">erlotinib</Keyword><Keyword MajorTopicYN="N">lung cancer</Keyword><Keyword MajorTopicYN="N">pulmonary fibrosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>30</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>12</Month><Day>21</Day><Hour>12</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>12</Month><Day>21</Day><Hour>10</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38126937</ArticleId><ArticleId IdType="doi">10.1002/rmv.2500</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>World Health Organization. WHO coronavirus (COVID-19) dashboard. Accessed 7 July 2023. https://covid19.who.int/</Citation></Reference><Reference><Citation>Maranatha D, Hasan H, Bakhtiar A, Widyoningroem A, Aryati. Association of TNF-&#x3b1;, TGF-&#x3b2;1, amphiregulin, IL-2, and EGFR WITH pulmonary fibrosis in COVID-19. J Infect Public Health. 2022;15(10):1072-1075. https://doi.org/10.1016/j.jiph.2022.08.007</Citation></Reference><Reference><Citation>Masi P, H&#xe9;kimian G, Lejeune M, et&#xa0;al. Systemic inflammatory response syndrome is a major contributor to COVID-19-associated coagulopathy: insights from a prospective, single-center cohort study. Circulation. 2020;142(6):611-614. https://doi.org/10.1161/circulationaha.120.048925</Citation></Reference><Reference><Citation>Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28(3):583-590. https://doi.org/10.1038/s41591-022-01689-3</Citation></Reference><Reference><Citation>Al-Ramadan A, Rabab&#x2019;h O, Shah J, Gharaibeh A. Acute and post-acute neurological complications of COVID-19. Neurol Int. 2021;13(1):102-119. https://doi.org/10.3390/neurolint13010010</Citation></Reference><Reference><Citation>G&#x105;secka A, Borovac JA, Guerreiro RA, et&#xa0;al. Thrombotic complications in patients with COVID-19: pathophysiological mechanisms, diagnosis, and treatment. Cardiovasc Drugs Ther. 2021;35(2):215-229. https://doi.org/10.1007/s10557-020-07084-9</Citation></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133-146. https://doi.org/10.1038/s41579-022-00846-2</Citation></Reference><Reference><Citation>Hussain A, Yang H, Zhang M, et&#xa0;al. mRNA vaccines for COVID-19 and diverse diseases. J Contr Release. 2022;345:314-333. https://doi.org/10.1016/j.jconrel.2022.03.032</Citation></Reference><Reference><Citation>Di Fusco M, Lin J, Vaghela S, et&#xa0;al. COVID-19 vaccine effectiveness among immunocompromised populations: a targeted literature review of real-world studies. Expert Rev Vaccines. 2022;21(4):435-451. https://doi.org/10.1080/14760584.2022.2035222</Citation></Reference><Reference><Citation>Zhang X, Lobinska G, Feldman M, et&#xa0;al. A spatial vaccination strategy to reduce the risk of vaccine-resistant variants. PLoS Comput Biol. 2022;18(8):1-27. https://doi.org/10.1371/journal.pcbi.1010391</Citation></Reference><Reference><Citation>Beeraka NM, Sukocheva OA, Lukina E, Liu J, Fan R. Development of antibody resistance in emerging mutant strains of SARS CoV-2: impediment for COVID-19 vaccines. Rev Med Virol. 2022;32(5):e2346. https://doi.org/10.1002/rmv.2346</Citation></Reference><Reference><Citation>Zhou U, Zheng R, Liu S, et&#xa0;al. Host E3 ligase HUWE1 attenuates the proapoptotic activity of the MERS-CoV accessory protein ORF3 by promoting its ubiquitin-dependent degradation. J Biol Chem. 2022;298(2):101584. https://doi.org/10.1016/j.jbc.2022.101584</Citation></Reference><Reference><Citation>Zhou Y, Zheng R, Liu D, et&#xa0;al. UBR5 acts as an antiviral host factor against MERS-CoV via promoting ubiquitination and degradation of ORF4b. In: Gallagher T, ed. J Virol. Vol 96; 2022.e0074122.</Citation></Reference><Reference><Citation>Farahani M, Niknam Z, Mohammadi Amirabad L, et&#xa0;al. Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets. Biomed Pharmacother. 2022;145:112420. https://doi.org/10.1016/j.biopha.2021.112420</Citation></Reference><Reference><Citation>Hemmat N, Asadzadeh Z, Karim N, et&#xa0;al. The roles of signaling pathways in SARS - CoV - 2 infection; lessons learned from SARS - CoV and MERS - CoV. Arch Virol. 2021;166(3):675-696. https://doi.org/10.1007/s00705-021-04958-7</Citation></Reference><Reference><Citation>Garbers C, Kuck F, Aparicio-Siegmund S, et&#xa0;al. Cellular senescence or EGFR signaling induces Interleukin 6 (IL-6) receptor expression controlled by mammalian target of rapamycin (mTOR). Cell Cycle. 2013;12(21):3421-3432. https://doi.org/10.4161/cc.26431</Citation></Reference><Reference><Citation>Xu Z, Shi L, Wang Y, et&#xa0;al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420-422. https://doi.org/10.1016/s2213-2600(20)30076-x</Citation></Reference><Reference><Citation>Kang YW, Lee SC, Jeon SM, Jo EK. Roles of interleukin-17 and th17 responses in Covid-19. J Bacteriol Virol. 2021;51(3):89-102. https://doi.org/10.4167/jbv.2021.51.3.089</Citation></Reference><Reference><Citation>Palakkott AR, Alneyadi A, Muhammad K, et&#xa0;al. The SARS-CoV-2 spike protein activates the epidermal growth factor receptor-mediated signaling. Vaccines. 2023;11(4):768. https://doi.org/10.3390/vaccines11040768</Citation></Reference><Reference><Citation>Wang S, Qiu Z, Hou Y, et&#xa0;al. AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells. Cell Res. 2021;31(2):126-140. https://doi.org/10.1038/s41422-020-00460-y</Citation></Reference><Reference><Citation>Purcaru OS, Artene SA, Barcan E, et&#xa0;al. The interference between&#xa0;sars-cov-2 and tyrosine kinase receptor signaling in cancer. Int J Mol Sci. 2021;22(9):4830. https://doi.org/10.3390/ijms22094830</Citation></Reference><Reference><Citation>Yoo J, Perez CER, Nie W, Edwards RA, Sinnett-Smith J, Rozengurt E. TNF-&#x3b1; induces upregulation of EGFR expression and signaling in human colonic myofibroblasts. Am J Physiol Liver Physiol. 2012;302(8):G805-G814. https://doi.org/10.1152/ajpgi.00522.2011</Citation></Reference><Reference><Citation>Zhang YG, Chen HW, Zhang HX, et&#xa0;al. EGFR activation impairs antiviral activity of interferon signaling in brain microvascular endothelial cells during Japanese encephalitis virus infection. Front Microbiol. 2022;13:1-16. https://doi.org/10.3389/fmicb.2022.894356</Citation></Reference><Reference><Citation>Hatabu H, Kaye KM, Christiani DC. Viral infection, pulmonary fibrosis, and long COVID. Am J Respir Crit Care Med. 2023;207(6):647-649. https://doi.org/10.1164/rccm.202211-2121ed</Citation></Reference><Reference><Citation>Venkataraman T, Coleman CM, Frieman MB. Overactive epidermal growth factor receptor signaling leads to increased fibrosis after severe acute respiratory syndrome coronavirus infection. J Virol. 2017;91(12):001822. https://doi.org/10.1128/jvi.00182-17</Citation></Reference><Reference><Citation>Normanno N, De Luca A, Bianco C, et&#xa0;al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366(1):2-16. https://doi.org/10.1016/j.gene.2005.10.018</Citation></Reference><Reference><Citation>Appelberg S, Gupta S, Svensson Akusj&#xe4;rvi S, et&#xa0;al. Dysregulation in Akt/mTOR/HIF-1 signaling identified by proteo-transcriptomics of SARS-CoV-2 infected cells. Emerg Microb Infect. 2020;9(1):1748-1760. https://doi.org/10.1080/22221751.2020.1799723</Citation></Reference><Reference><Citation>Fattahi S, Khalifehzadeh-Esfahani Z, Mohammad-Rezaei M, Mafi S, Jafarinia M. PI3K/Akt/mTOR pathway: a potential target for anti-SARS-CoV-2 therapy. Immunol Res. 2022;70(3):269-275. https://doi.org/10.1007/s12026-022-09268-x</Citation></Reference><Reference><Citation>Wang Z, Xing Y, Li B, Li X, Liu B, Wang Y. Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer. Mol Biomed. 2022;3(1):42. https://doi.org/10.1186/s43556-022-00107-x</Citation></Reference><Reference><Citation>Rosell R, Moran T, Queralt C, et&#xa0;al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958-967. https://doi.org/10.1056/nejmoa0904554</Citation></Reference><Reference><Citation>Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol Oncol. 2018;12(1):3-20. https://doi.org/10.1002/1878-0261.12155</Citation></Reference><Reference><Citation>Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001;37:S3-S8. https://doi.org/10.1016/s0959-8049(01)00230-1</Citation></Reference><Reference><Citation>Linggi B, Carpenter G. ErbB receptors: new insights on mechanisms and biology. Trends Cell Biol. 2006;16(12):649-656. https://doi.org/10.1016/j.tcb.2006.10.008</Citation></Reference><Reference><Citation>Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res. 2006;12(18):5268-5272. https://doi.org/10.1158/1078-0432.ccr-05-1554</Citation></Reference><Reference><Citation>Wieduwilt MJ, Moasser MM. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci. 2011;65(10):1566-1584. https://doi.org/10.1007/s00018-008-7440-8</Citation></Reference><Reference><Citation>Coffey RJ, Romano M, Polk WH, Dempsey PJ. Roles for transforming growth factor-alpha in gastric physiology and pathophysiology. Yale J Biol Med. 1992;65:693.</Citation></Reference><Reference><Citation>Daniel CR, Bostick RM, Flanders WD, et&#xa0;al. TGF-alpha expression as a potential biomarker of risk within the normal-appearing colorectal mucosa of patients with and without incident sporadic adenoma. Cancer Epidemiol biomarkers Prev a Publ Am Assoc Cancer Res cosponsored by Am Soc Prev Oncol. 2009;18(1):65-73. https://doi.org/10.1158/1055-9965.epi-08-0732</Citation></Reference><Reference><Citation>Rah B, Rather RA, Bhat GR, et&#xa0;al. JAK/STAT signaling: molecular targets, therapeutic opportunities, and limitations of targeted inhibitions in solid malignancies. Front Pharmacol. 2022;13:1-19. https://doi.org/10.3389/fphar.2022.821344</Citation></Reference><Reference><Citation>Rane SG, Reddy EP. Janus kinases: components of multiple signaling pathways. Oncogene. 2000;19(49):5662-5679. https://doi.org/10.1038/sj.onc.1203925</Citation></Reference><Reference><Citation>Parakh S, Ernst M, Poh AR. Multicellular effects of STAT3 in non-small cell lung cancer: mechanistic insights and therapeutic opportunities. Cancers (Basel). 2021;13(24):6228. https://doi.org/10.3390/cancers13246228</Citation></Reference><Reference><Citation>Diao J, Pantua H, Ngu H, et&#xa0;al. Hepatitis C virus induces epidermal growth factor receptor activation via CD81 binding for viral internalization and entry. J Virol. 2012;86(20):10935-10949. https://doi.org/10.1128/jvi.00750-12</Citation></Reference><Reference><Citation>Lupberger J, Zeisel MB, Xiao F, et&#xa0;al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med. 2011;17(5):589-595. https://doi.org/10.1038/nm.2341</Citation></Reference><Reference><Citation>Monick MM, Cameron K, Staber J, et&#xa0;al. Activation of the epidermal growth factor receptor by respiratory syncytial virus results in increased inflammation and delayed apoptosis. J Biol Chem. 2005;280(3):2147-2158. https://doi.org/10.1074/jbc.m408745200</Citation></Reference><Reference><Citation>Jia Z, Bao K, Wei P, et&#xa0;al. EGFR activation-induced decreases in claudin1 promote MUC5AC expression and exacerbate asthma in mice. Mucosal Immunol. 2021;14(1):125-134. https://doi.org/10.1038/s41385-020-0272-z</Citation></Reference><Reference><Citation>Thai P, Loukoianov A, Wachi S, Wu R. Regulation of airway mucin gene expression. Annu Rev Physiol. 2008;70(1):405-429. https://doi.org/10.1146/annurev.physiol.70.113006.100441</Citation></Reference><Reference><Citation>Hu W, Zhang S, Shen Y, Yang Q. Epidermal growth factor receptor is a co-factor for transmissible gastroenteritis virus entry. Virology. 2018;521:33-43. https://doi.org/10.1016/j.virol.2018.05.009</Citation></Reference><Reference><Citation>Hu W, Zhu L, Yang X, Lin J, Yang Q. The epidermal growth factor receptor regulates cofilin activity and promotes transmissible gastroenteritis virus entry into intestinal epithelial cells. Oncotarget. 2016;7(11):12206-12221. https://doi.org/10.18632/oncotarget.7723</Citation></Reference><Reference><Citation>Dong W, Xie W, Liu Y, et&#xa0;al. Receptor tyrosine kinase inhibitors block proliferation of TGEV mainly through p38 mitogen-activated protein kinase pathways. Antivir Res. 2020;173:104651. https://doi.org/10.1016/j.antiviral.2019.104651</Citation></Reference><Reference><Citation>Kung CP, Meckes DG, Raab-Traub N. Epstein-Barr virus LMP1 activates EGFR, STAT3, and ERK through effects on PKCdelta. J Virol. 2011;85(9):4399-4408. https://doi.org/10.1128/jvi.01703-10</Citation></Reference><Reference><Citation>Eierhoff T, Hrincius ER, Rescher U, Ludwig S, Ehrhardt C. The epidermal growth factor receptor (EGFR) promotes uptake of influenza a viruses (IAV) into host cells. Fouchier RAM. PLoS Pathog. 2010;6(9):e1001099. https://doi.org/10.1371/journal.ppat.1001099</Citation></Reference><Reference><Citation>Klann K, Bojkova D, Tascher G, Ciesek S, M&#xfc;nch C, Cinatl J. Growth factor receptor signaling inhibition prevents SARS-CoV-2 replication. Mol Cell. 2020;80(1):164-174.e4. https://doi.org/10.1016/j.molcel.2020.08.006</Citation></Reference><Reference><Citation>Engler M, Albers D, Von Maltitz P, Gro&#xdf; R, M&#xfc;nch J, Cirstea IC. ACE2-EGFR-MAPK signaling contributes to SARS-CoV-2 infection. Life Sci Alliance. 2023;6(9):e202201880. https://doi.org/10.26508/lsa.202201880</Citation></Reference><Reference><Citation>Shin HJ, Ku KB, Yoon GY, et&#xa0;al. SARS-CoV-2 aberrantly elevates mitochondrial bioenergetics to induce robust virus propagation. Euro PMC. 2021. https://doi.org/10.21203/rs.3.rs-593889/v1</Citation></Reference><Reference><Citation>Matsuyama T, Kubli SP, Yoshinaga SK, Pfeffer K, Mak TW. An aberrant STAT pathway is central to COVID-19. Cell Death Differ. 2020;27(12):3209-3225. https://doi.org/10.1038/s41418-020-00633-7</Citation></Reference><Reference><Citation>Londres HD, Armada JJ, Mart&#xed;nez AH, et&#xa0;al. Blocking EGFR with nimotuzumab: a novel strategy for COVID-19 treatment. Immunotherapy. 2022;14(7):521-530. https://doi.org/10.2217/imt-2022-0027</Citation></Reference><Reference><Citation>Alberti C, Pinciroli P, Valeri B, et&#xa0;al. Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer. Oncogene. 2012;31(37):4139-4149. https://doi.org/10.1038/onc.2011.572</Citation></Reference><Reference><Citation>Kang S, Tanaka T, Inoue H, et&#xa0;al. IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome. Proc Natl Acad Sci U S A. 2020;117(36):22351-22356. https://doi.org/10.1073/pnas.2010229117</Citation></Reference><Reference><Citation>Song P, Li W, Xie J, Hou Y, You C. Cytokine storm induced by SARS-CoV-2. Clin Chim Acta. 2020;509:280-287. https://doi.org/10.1016/j.cca.2020.06.017</Citation></Reference><Reference><Citation>Khan I, Hatiboglu MA. Can COVID-19 induce glioma tumorogenesis through binding cell receptors? Med Hypotheses. 2020;144:110009. https://doi.org/10.1016/j.mehy.2020.110009</Citation></Reference><Reference><Citation>Schramm F, Schaefer L, Wygrecka M. EGFR signaling in lung fibrosis. Cells. 2022;11(6):1-15. https://doi.org/10.3390/cells11060986</Citation></Reference><Reference><Citation>Purba ER, Saita EI, Maruyama IN. Activation of the EGF receptor by ligand binding and oncogenic mutations: the &#x201c;rotation model.&#x201d;. Cells. 2017;6(2):1-19. https://doi.org/10.3390/cells6020013</Citation></Reference><Reference><Citation>Jorissen RN, Walker F, Pouliot N, Garrett TPJ, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res. 2003;284(1):31-53. https://doi.org/10.1016/s0014-4827(02)00098-8</Citation></Reference><Reference><Citation>Tzouvelekis A, Gomatou G, Bouros E, Trigidou R, Tzilas V, Bouros D. Common pathogenic mechanisms between idiopathic pulmonary fibrosis and lung cancer. Chest. 2019;156(2):383-391. https://doi.org/10.1016/j.chest.2019.04.114</Citation></Reference><Reference><Citation>Karampitsakos T, Tzilas V, Tringidou R, et&#xa0;al. Lung cancer in patients with idiopathic pulmonary fibrosis. Pulm Pharmacol Ther. 2017;45:1-10. https://doi.org/10.1016/j.pupt.2017.03.016</Citation></Reference><Reference><Citation>Vagapova ER, Lebedev TD, Prassolov VS. Viral fibrotic scoring and drug screen based on MAPK activity uncovers EGFR as a key regulator of COVID-19 fibrosis. Sci Rep. 2021;11:1-14. https://doi.org/10.1038/s41598-021-90701-w</Citation></Reference><Reference><Citation>Burgel PR, Nadel JA. Roles of epidermal growth factor receptor activation in epithelial cell repair and mucin production in airway epithelium. Thorax. 2004;59(11):992-996. https://doi.org/10.1136/thx.2003.018879</Citation></Reference><Reference><Citation>Kato T, Asakura T, Edwards CE, et&#xa0;al. Prevalence and mechanisms of mucus accumulation in COVID-19 lung disease. Am J Respir Crit Care Med. 2022;206(11):1336-1352. https://doi.org/10.1164/rccm.202111-2606oc</Citation></Reference><Reference><Citation>Zhang Y, Wang Z, Zhang Y, Tong H, Zhang Y, Lu T. Potential mechanisms for traditional Chinese medicine in treating airway mucus hypersecretion associated with coronavirus disease 2019. Front Mol Biosci. 2020;7:1-14. https://doi.org/10.3389/fmolb.2020.577285</Citation></Reference><Reference><Citation>Konopka KE, Wilson A, Myers JL. Postmortem lung findings in a patient with asthma and coronavirus disease 2019. Chest. 2020;158(3):e99-e101. https://doi.org/10.1016/j.chest.2020.04.032</Citation></Reference><Reference><Citation>Yin W, Cao W, Zhou G, et&#xa0;al. Analysis of pathological changes in the epithelium in COVID-19 patient airways. ERJ open Res. 2021;7(2):00690-02020. https://doi.org/10.1183/23120541.00690-2020</Citation></Reference><Reference><Citation>Bhatia R, Gautam SK, Cannon A, et&#xa0;al. Cancer-associated mucins: role in immune modulation and metastasis. Cancer Metastasis Rev. 2019;38(1-2):223-236. https://doi.org/10.1007/s10555-018-09775-0</Citation></Reference><Reference><Citation>Lu W, Liu X, Wang T, et&#xa0;al. Elevated MUC1 and MUC5AC mucin protein levels in airway mucus of critical ill COVID-19 patients. J Med Virol. 2021;93(2):582-584. https://doi.org/10.1002/jmv.26406</Citation></Reference><Reference><Citation>Ye Z, Zhang Y, Wang Y, Huang Z, Song B. Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review. Eur Radiol. 2020;30(8):4381-4389. https://doi.org/10.1007/s00330-020-06801-0</Citation></Reference><Reference><Citation>Roskoski R. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Pharmacol Res. 2019;139:395-411. https://doi.org/10.1016/j.phrs.2018.11.014</Citation></Reference><Reference><Citation>Yenerall P, Kittler R, Minna J. Structure-based classification of EGFR mutations informs inhibitor selection for lung cancer therapy. Cancer Cell. 2021;39(11):1455-1457. https://doi.org/10.1016/j.ccell.2021.10.012</Citation></Reference><Reference><Citation>Kalinowski A, Galen BT, Ueki IF, et&#xa0;al. Respiratory syncytial virus activates epidermal growth factor receptor to suppress interferon regulatory factor 1-dependent interferon-lambda and antiviral defense in airway epithelium. Mucosal Immunol. 2018;11(3):958-967. https://doi.org/10.1038/mi.2017.120</Citation></Reference><Reference><Citation>Gan CJ, Li WF, Li CN, Li LL, Zhou WY, Peng XM. EGF receptor inhibitors comprehensively suppress hepatitis B virus by downregulation of STAT3 phosphorylation. Biochem Biophys Reports. 2020;22:100763. https://doi.org/10.1016/j.bbrep.2020.100763</Citation></Reference><Reference><Citation>Kitazaki T, Oka M, Nakamura Y, et&#xa0;al. Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer. 2005;49(3):337-343. https://doi.org/10.1016/j.lungcan.2005.03.035</Citation></Reference><Reference><Citation>Tsang RY, Sadeghi S, Finn RS. Lapatinib, a Dual-targeted small molecule inhibitor of EGFR and HER2, in HER2-Amplified breast cancer: from bench to bedside. Clin Med Insights Ther. 2011;3:1-13. https://doi.org/10.4137/cmt.s3783</Citation></Reference><Reference><Citation>Rabindran SK, Discafani CM, Rosfjord EC, et&#xa0;al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res. 2004;64(11):3958-3965. https://doi.org/10.1158/0008-5472.can-03-2868</Citation></Reference><Reference><Citation>Schettino C, Bareschino MA, Ricci V, Ciardiello F. Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment. Expet Rev Respir Med. 2008;2:167-178. https://doi.org/10.1586/17476348.2.2.167</Citation></Reference><Reference><Citation>Venkataraman T, Frieman MB. The role of epidermal growth factor receptor (EGFR) signaling in SARS coronavirus-induced pulmonary fibrosis. Antivir Res. 2017;143:142-150. https://doi.org/10.1016/j.antiviral.2017.03.022</Citation></Reference><Reference><Citation>Mok TS, Cheng Y, Zhou X, et&#xa0;al. Updated overall survival in a randomized study comparing dacomitinib with gefitinib as first-line treatment in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. Drugs. 2021;81(2):257-266. https://doi.org/10.1007/s40265-020-01441-6</Citation></Reference><Reference><Citation>Sun H, Wu YL. Dacomitinib in non-small-cell lung cancer: a comprehensive review for clinical application. Future Oncol. 2019;15(23):2769-2777. https://doi.org/10.2217/fon-2018-0535</Citation></Reference><Reference><Citation>Hochmair MJ, Morabito A, Hao D, et&#xa0;al. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study. Future Oncol. 2020;16(34):2799-2808. https://doi.org/10.2217/fon-2020-0740</Citation></Reference><Reference><Citation>Vasconcelos PENS, Kobayashi IS, Kobayashi SS, Costa DB. Preclinical characterization of mobocertinib highlights the putative therapeutic window of this novel EGFR inhibitor to EGFR exon 20 insertion mutations. JTO Clin Res Rep. 2021;2(3):100105. https://doi.org/10.1016/j.jtocrr.2020.100105</Citation></Reference><Reference><Citation>Carabelli AM, Peacock TP, Thorne LG, et&#xa0;al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol. 2023;21:162-177. https://doi.org/10.1038/s41579-022-00841-7</Citation></Reference><Reference><Citation>Moreno S, Perno C, Mallon P, et&#xa0;al. Two-drug vs. three-drug combinations for HIV-1: do we have enough data to make the switch? HIV Med. 2019;20(S4):2-12. https://doi.org/10.1111/hiv.12716</Citation></Reference><Reference><Citation>Diaz H, Jim&#xe9;nez J, Hern&#xe1;ndez A, et&#xa0;al. Nimotuzumab increases the recovery rate of severe and critical COVID-19 patients: evaluation in the real-world scenario. Front Public Health. 2022;10:1-7. https://doi.org/10.3389/fpubh.2022.948520</Citation></Reference><Reference><Citation>Haspinger ER, Agustoni F, Torri V, et&#xa0;al. Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations. Crit Rev Oncol Hematol. 2015;94(2):213-227. https://doi.org/10.1016/j.critrevonc.2014.11.005</Citation></Reference><Reference><Citation>Haaland B, Tan PS, De Castro G, Lopes G. Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations. J Thorac Oncol. 2014;9(6):805-811. https://doi.org/10.1097/jto.0000000000000156</Citation></Reference><Reference><Citation>Park K, Tan EH, O&#x2019;Byrne K, et&#xa0;al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17(5):577-589. https://doi.org/10.1016/s1470-2045(16)30033-x</Citation></Reference><Reference><Citation>Passaro A, Di Maio M, Del Signore E, Gori B, de Marinis F. Management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: a comparison analysis. Clin Lung Cancer. 2014;15(4):307-312. https://doi.org/10.1016/j.cllc.2014.04.006</Citation></Reference><Reference><Citation>Goss GD, Cobo M, Lu S, et&#xa0;al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: final analysis of the randomised phase 3 LUX-Lung 8 trial. eClinicalMedicine. 2021;37:100940. https://doi.org/10.1016/j.eclinm.2021.100940</Citation></Reference><Reference><Citation>Thomas P, Vincent B, George C, Joshua JM, Pavithran K, Vijayan M. A comparative study on erlotinib &amp; gefitinib therapy in non-small cell lung carcinoma patients. Indian J Med Res. 2019;150(1):67-72. https://doi.org/10.4103/ijmr.ijmr_1896_17</Citation></Reference><Reference><Citation>Jakopovic M, Cucevic B, Plestina S, et&#xa0;al. Safety and efficacy of erlotinib in patients with squamous cell lung cancer. Eur Respir J. 2014;44:P2722.</Citation></Reference><Reference><Citation>Bekerman E, Neveu G, Shulla A, et&#xa0;al. Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects. J Clin Invest. 2017;127(4):1338-1352. https://doi.org/10.1172/jci89857</Citation></Reference><Reference><Citation>Mansouri K, Rastegari-Pouyani M, Ghanbri-Movahed M, Safarzadeh M, Kiani S, Ghanbari-Movahed Z. Can a metabolism-targeted therapeutic intervention successfully subjugate SARS-COV-2? A scientific rational. Biomed Pharmacother. 2020;131:110694. https://doi.org/10.1016/j.biopha.2020.110694</Citation></Reference><Reference><Citation>Bethune G, Bethune D, Ridgway N, Xu Z. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. J Thorac Dis. 2010;2:48-51.</Citation></Reference><Reference><Citation>Frohna P, Lu J, Eppler S, et&#xa0;al. Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects. J Clin Pharmacol. 2006;46(3):282-290. https://doi.org/10.1177/0091270005284193</Citation></Reference><Reference><Citation>Vavougios GD, Breza M, Mavridis T, Krogfelt KA. FYN, SARS-CoV-2, and IFITM3 in the neurobiology of Alzheimer&#x2019;s disease. Brain Disord. 2021;3:100022. https://doi.org/10.1016/j.dscb.2021.100022</Citation></Reference><Reference><Citation>Barben J, Quipourt V, Vovelle J, Putot A, Manckoundia P. Not Covid-19, don&#x2019;t overlook pneumocystis in patients on gefitinib. Curr Oncol. 2021;28(1):961-964. https://doi.org/10.3390/curroncol28010094</Citation></Reference><Reference><Citation>Zhang YY, Liang R, Wang SJ, et&#xa0;al. SARS-CoV-2 hijacks macropinocytosis to facilitate its entry and promote viral spike-mediated cell-to-cell fusion. J Biol Chem. 2022;298(11):102511. https://doi.org/10.1016/j.jbc.2022.102511</Citation></Reference><Reference><Citation>Braga L, Ali H, Secco I, et&#xa0;al. Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia. Nature. 2021;594(7861):88-93. https://doi.org/10.1038/s41586-021-03491-6</Citation></Reference><Reference><Citation>Pingali MS, Singh A, Singh V, Sahoo AK, Varadwaj PK, Samanta SK. Docking and molecular dynamics simulation for therapeutic repurposing in small cell lung cancer (SCLC) patients infected with COVID-19. J Biomol Struct Dyn. 2023;41(1):16-25. https://doi.org/10.1080/07391102.2021.2002719</Citation></Reference><Reference><Citation>Ghahremanpour MM, Tirado-Rives J, Deshmukh M, et&#xa0;al. Identification of 14 known drugs as inhibitors of the main protease of SARS-CoV-2. ACS Med Chem Lett. 2020;11(12):2526-2533. https://doi.org/10.1021/acsmedchemlett.0c00521</Citation></Reference><Reference><Citation>Drayman N, Jones KA, Azizi SA, et&#xa0;al. Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that replication of SARS-CoV-2. Science. 2021;373(6557):931-936. https://doi.org/10.1126/science.abg5827</Citation></Reference><Reference><Citation>Yuan Y, Lee JS, Yost SE, et&#xa0;al. Phase II study of neratinib in older adults with HER2 amplified or HER2/3 mutated metastatic breast cancer. J Geriatr Oncol. 2021;12(5):752-758. https://doi.org/10.1016/j.jgo.2021.02.020</Citation></Reference><Reference><Citation>Li Q, Wang Z, Zheng Q, Liu S. Potential clinical drugs as covalent inhibitors of the priming proteases of the spike protein of SARS-CoV-2. Comput Struct Biotechnol J. 2020;18:2200-2208. https://doi.org/10.1016/j.csbj.2020.08.016</Citation></Reference><Reference><Citation>Camidge DR, Barlesi F, Goldman JW, et&#xa0;al. Phase ib study of telisotuzumab vedotin in combination with erlotinib in patients with c-met protein-expressing non-small-cell lung cancer. J Clin Oncol. 2023;41(5):1105-1115. https://doi.org/10.1200/jco.22.00739</Citation></Reference><Reference><Citation>Bui N, Wong-Sefidan I. Reactivation of hepatitis B virus after withdrawal of erlotinib. Curr Oncol. 2015;22(6):430-432. https://doi.org/10.3747/co.22.2665</Citation></Reference><Reference><Citation>Neveu G, Ziv-Av A, Barouch-Bentov R, Berkerman E, Mulholland J, Einav S. AP-2-Associated protein kinase 1 and Cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets. J Virol. 2015;89(8):4387-4404. https://doi.org/10.1128/jvi.02705-14</Citation></Reference><Reference><Citation>Pu SY, Xiao F, Schor S, et&#xa0;al. Feasibility and biological rationale of&#xa0;repurposing sunitinib and erlotinib for dengue treatment. Antivir&#xa0;Res. 2018;155:67-75. https://doi.org/10.1016/j.antiviral.2018.05.001</Citation></Reference><Reference><Citation>Laise P, Bosker G, Sun X, et&#xa0;al. The host cell ViroCheckpoint: identification and pharmacologic targeting of novel mechanistic determinants of coronavirus-mediated hijacked cell states. bioRxiv Prepr Serv Biol. 2020:1-20. https://doi.org/10.1101/2020.05.12.091256</Citation></Reference><Reference><Citation>de Bruin G, Demont D, de Zwart E, et&#xa0;al. Discovery of quinoline-based irreversible BTK inhibitors. Bioorg Med Chem Lett. 2020;30(14):127261. https://doi.org/10.1016/j.bmcl.2020.127261</Citation></Reference><Reference><Citation>Anju A, Chaturvedi S, Chaudhary V, Pant P, Hussain F, Mishra AK. Virtual screening of quinoline derived library for SARS-COV-2 targeting viral entry and replication. J Biomol Struct Dyn. 2022;40(18):8464-8493. https://doi.org/10.1080/07391102.2021.1913228</Citation></Reference><Reference><Citation>Dittmar M, Lee JS, Whig K, et&#xa0;al. Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2. Cell Rep. 2021;35(1):108959. https://doi.org/10.1016/j.celrep.2021.108959</Citation></Reference><Reference><Citation>Chen XM, Pradhan M, Gorshkov K, et&#xa0;al. Identifying SARS-CoV-2 entry inhibitors through drug repurposing screens of SARS-S and MERS-S pseudotyped particles. ACS Pharmacol Transl Sci. 2020;3(6):1165-1175. https://doi.org/10.1021/acsptsci.0c00112</Citation></Reference><Reference><Citation>Naik RR, Shakya AK, Aladwan SM, El-Tanani M. Kinase inhibitors as potential therapeutic agents in the treatment of COVID-19. Front Pharmacol. 2022;13:1-12. https://doi.org/10.3389/fphar.2022.806568</Citation></Reference><Reference><Citation>Jeon S, Ko M, Lee J, et&#xa0;al. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. Antimicrob Agents Chemother. 2020;64(7):e00819. https://doi.org/10.1128/aac.00819-20</Citation></Reference><Reference><Citation>Wang J, Lam D, Yang J, Hu L. Discovery of mobocertinib, a new irreversible tyrosine kinase inhibitor indicated for the treatment of non-small-cell lung cancer harboring EGFR exon 20 insertion mutations. Med Chem Res. 2022;31(10):1647-1662. https://doi.org/10.1007/s00044-022-02952-5</Citation></Reference><Reference><Citation>Schoggins JW. Regulating interferon antiviral activity: a role for&#xa0;epidermal growth factor receptor. Hepatology. 2013;58(4):1200-1202. https://doi.org/10.1002/hep.26486</Citation></Reference><Reference><Citation>De S, Zhou H, DeSantis D, Croniger CM, Li X, Stark GR. Erlotinib protects against LPS-induced Endotoxicity because TLR4 needs EGFR to signal. Proc Natl Acad Sci USA. 2015;112(31):9680-9685. https://doi.org/10.1073/pnas.1511794112</Citation></Reference><Reference><Citation>Jia F, Wang G, Xu J, Long J, Deng F, Jiang W. Role of tumor necrosis factor-&#x3b1; in the mortality of hospitalized patients with severe and critical COVID-19 pneumonia. Aging (Albany NY). 2021;13(21):23895-23912. https://doi.org/10.18632/aging.203663</Citation></Reference><Reference><Citation>Yoo J, Rodriguez Perez CE, Nie W, Edwards RA, Sinnett-Smith J, Rozengurt E. TNF-&#x3b1; induces upregulation of EGFR expression and signaling in human colonic myofibroblasts. Am J Physiol Gastrointest Liver Physiol. 2012;302(8):G805-G814. https://doi.org/10.1152/ajpgi.00522.2011</Citation></Reference><Reference><Citation>Luo Q, Gu Y, Zheng W, et&#xa0;al. Erlotinib inhibits T-cell-mediated immune response via down-regulation of the c-Raf/ERK cascade and Akt signaling pathway. Toxicol Appl Pharmacol. 2011;251(2):130-136. https://doi.org/10.1016/j.taap.2010.12.011</Citation></Reference><Reference><Citation>Wang X, Wang H, Yin G, Zhang YD. Network-based drug repurposing for the treatment of COVID-19 patients in different clinical stages. Heliyon. 2023;9(3):e14059. https://doi.org/10.1016/j.heliyon.2023.e14059</Citation></Reference><Reference><Citation>Kar P, Saleh-E-In MM, Jaishee N, et&#xa0;al. Computational profiling of natural compounds as promising inhibitors against the spike proteins of SARS-CoV-2 wild-type and the variants of concern, viral cell-entry process, and cytokine storm in COVID-19. J Cell Biochem. 2022;123(5):964-986. https://doi.org/10.1002/jcb.30243</Citation></Reference><Reference><Citation>Stebbing J, Phelan A, Griffin I, et&#xa0;al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20(4):400-402. https://doi.org/10.1016/s1473-3099(20)30132-8</Citation></Reference><Reference><Citation>Richardson P, Griffin I, Tucker C, et&#xa0;al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395(10223):e30-e31. https://doi.org/10.1016/s0140-6736(20)30304-4</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>